To verify these GS development-related genes, we used the prostate cancer of The Cancer Genome Atlas (TCGA-PRAD) dataset and evaluated the expression levels of 117 intersecting genes (among the 120 simultaneously dysregulated genes, the expression of 1 excluded gene, TOMM6, was 0, and 2 excluded genes, AP004608.1 and H3F3A, were not identified in TCGA-PRAD dataset) associated with various clinicopathological characteristics. This evidence concerns the gene TOMM6 and prostate cancer.